Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9248001 | 0.80 | TSHR (0.45) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL16329878 | 0.78 | HPGD (0.45) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL4270217 | 0.77 | TSHR (0.47) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL10528507 | 0.76 | TSHR (0.41) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL15970521 | 0.76 | MAOA (0.41) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL28510555 | 0.76 | TSHR (0.41) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL4711341 | 0.74 | NPC1 (0.43) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL30357156 | 0.74 | SMN1; SMN2 (0.43) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL39369 | 0.74 | TSHR (0.50) | TSHRACHESMN1; SMN2HPGDERCC5 | |
| SCHEMBL2451836 | 0.74 | TSHR (0.50) | TSHRACHESMN1; SMN2HPGDERCC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895545-B2 | Acrylamide derivatives as Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20130267714-A1 | BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS | SOLVIAS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-09-12 | — | — | US | disclosed |
| US-8450501-B2 | Bidentate chiral ligands for use in catalytic asymmetric addition reactions | SOLVIAS AG (CH) | 2013-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237523-A1 | ACRYLAMIDE DERIVATIVES AS FAB I INHIBITORS | ACR, DBI, AADAC | TSHR 3272/4885ACHE 1458/4885SMN1; SMN2 4763/4885 |
| US-20130267714-A1 | BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS | C1R, PNISR, CBR1 | TSHR 512/4885ACHE 1920/4885SMN1; SMN2 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.